Tscan Therapeutics Stock Market Value
| TCRX Stock | USD 1.01 0.01 0.98% |
| Symbol | Tscan |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tscan Therapeutics. If investors know Tscan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tscan Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.12) | Revenue Per Share | Quarterly Revenue Growth 1.394 | Return On Assets | Return On Equity |
Understanding Tscan Therapeutics requires distinguishing between market price and book value, where the latter reflects Tscan's accounting equity. The concept of intrinsic value - what Tscan Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Tscan Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Tscan Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tscan Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tscan Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Tscan Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Tscan Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Tscan Therapeutics.
| 11/27/2025 |
| 02/25/2026 |
If you would invest 0.00 in Tscan Therapeutics on November 27, 2025 and sell it all today you would earn a total of 0.00 from holding Tscan Therapeutics or generate 0.0% return on investment in Tscan Therapeutics over 90 days. Tscan Therapeutics is related to or competes with Creative Medical, Aprea Therapeutics, Adial Pharmaceuticals, Kiora Pharmaceuticals, Cardio Diagnostics, and Phio Pharmaceuticals. TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell ther... More
Tscan Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Tscan Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Tscan Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.94 | |||
| Information Ratio | 0.0132 | |||
| Maximum Drawdown | 21.37 | |||
| Value At Risk | (5.61) | |||
| Potential Upside | 9.62 |
Tscan Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tscan Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Tscan Therapeutics' standard deviation. In reality, there are many statistical measures that can use Tscan Therapeutics historical prices to predict the future Tscan Therapeutics' volatility.| Risk Adjusted Performance | 0.0354 | |||
| Jensen Alpha | 0.1685 | |||
| Total Risk Alpha | (0.39) | |||
| Sortino Ratio | 0.0154 | |||
| Treynor Ratio | (0.82) |
Tscan Therapeutics February 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0354 | |||
| Market Risk Adjusted Performance | (0.81) | |||
| Mean Deviation | 3.31 | |||
| Semi Deviation | 3.35 | |||
| Downside Deviation | 3.94 | |||
| Coefficient Of Variation | 2835.25 | |||
| Standard Deviation | 4.58 | |||
| Variance | 21.01 | |||
| Information Ratio | 0.0132 | |||
| Jensen Alpha | 0.1685 | |||
| Total Risk Alpha | (0.39) | |||
| Sortino Ratio | 0.0154 | |||
| Treynor Ratio | (0.82) | |||
| Maximum Drawdown | 21.37 | |||
| Value At Risk | (5.61) | |||
| Potential Upside | 9.62 | |||
| Downside Variance | 15.54 | |||
| Semi Variance | 11.2 | |||
| Expected Short fall | (4.71) | |||
| Skewness | 1.07 | |||
| Kurtosis | 1.81 |
Tscan Therapeutics Backtested Returns
Tscan Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0149, which indicates the firm had a -0.0149 % return per unit of risk over the last 3 months. Tscan Therapeutics exposes thirty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Tscan Therapeutics' Risk Adjusted Performance of 0.0354, coefficient of variation of 2835.25, and Semi Deviation of 3.35 to confirm the risk estimate we provide. The entity has a beta of -0.19, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Tscan Therapeutics are expected to decrease at a much lower rate. During the bear market, Tscan Therapeutics is likely to outperform the market. At this point, Tscan Therapeutics has a negative expected return of -0.0661%. Please make sure to validate Tscan Therapeutics' rate of daily change, relative strength index, as well as the relationship between the semi variance and sortino ratio , to decide if Tscan Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.08 |
Virtually no predictability
Tscan Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Tscan Therapeutics time series from 27th of November 2025 to 11th of January 2026 and 11th of January 2026 to 25th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Tscan Therapeutics price movement. The serial correlation of 0.08 indicates that barely 8.0% of current Tscan Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.08 | |
| Spearman Rank Test | -0.26 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.